Advertisement
Brief report| Volume 99, ISSUE 11, P2370-2372, November 2018

Should the 6-Minute Walk Test Be Stopped If Oxyhemoglobin Saturation Falls Below 80%?

Published:August 18, 2018DOI:https://doi.org/10.1016/j.apmr.2018.07.426

      Highlights

      • There are no data to support recommendation for 6-minute walk test (6MWT) termination if oxyhemoglobin saturation <80%.
      • Retrospective audit of tests was conducted in stable patients by experienced clinicians.
      • A total of 672 tests were reviewed; 2 adverse events were recorded during tests without desaturation.
      • Findings do not support 6MWT termination due to desaturation.

      Abstract

      Objective

      To examine the occurrence of adverse events in patients undergoing assessment for pulmonary rehabilitation when a 6-minute walk test (6MWT) continues despite desaturation below 80%.

      Design

      Retrospective audit following REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement.

      Setting

      Large teaching hospital.

      Participants

      All patients (N=549) (55% men, mean age 69±11y) assessed for pulmonary rehabilitation (September 2005 to January 2016).

      Interventions

      The standardized tests were conducted by experienced cardiorespiratory physiotherapists. Oxyhemoglobin saturation was monitored continuously using a pulse oximeter (lowest value used for analysis). Medical records were reviewed, and adverse events defined as tachycardia, bradycardia, chest pain, or other sign/symptom necessitating cessation.

      Main Outcome Measure

      6MWT.

      Results

      Data from 672 walk tests were included with mean distance 369 (124) meters. The main diagnoses were chronic obstructive pulmonary disease (70%), interstitial lung disease (14%), and bronchiectasis (8%). Sixty individuals (11%) recorded desaturation below 80% without adverse events. Two adverse events were recorded during tests without desaturation; in 1 instance, chest pain with no evidence of cardiorespiratory compromise and in another, the patient stopped due to concern regarding blood sugar levels (11.5 mmol/L when tested). Independent predictors of desaturation to less than 80% were resting oxyhemoglobin saturation <95% (odds ratio [OR] 3.82, 95% confidence interval [CI] 2.06-7.08) and a diagnosis of interstitial lung disease or pulmonary arterial hypertension (OR 5.24, 95% CI 2.59-10.58).

      Conclusions

      This study found that desaturation to less than 80% during a 6MWT was not associated with adverse events in a large cohort of patients referred to pulmonary rehabilitation and assessed by experienced physiotherapists, suggesting that test cessation due to desaturation in stable patients may be unwarranted.

      Keywords

      List of abbreviations:

      6MWT (6-minute walk test), 6MWD (6-minute walk distance), CI (confidence interval), OR (odds ratio), RECORD (REporting of studies Conducted using Observational Routinely-collected health Data), SpO2 (oxyhemoglobin saturation)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Archives of Physical Medicine and Rehabilitation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Holland A.E.
        • Spruit M.A.
        • Troosters T.
        • et al.
        An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease.
        Eur Respir J. 2014; 44: 1428-1446
        • Piaggi G.
        • Gambazza S.
        • Guarise R.
        • Piran M.
        Pulse oximetry oxygen sauration during the 6-min walk test: a limit for stopping the test without resuming it.
        Eur Respir J. 2015; 46: 1222-1223
      1. ATS statement: guidelines for the six-minute walk test.
        Am J Respir Crit Care Med. 2002; 166: 111-117
        • Fiore C.B.
        • Lee A.L.
        • McDonald C.F.
        • Hill C.J.
        • Holland A.E.
        Should oxyhaemoglobin saturation be monitored continuously during the 6-minute walk test?.
        Chron Respir Dis. 2011; 8: 181-184
        • Benchimol E.I.
        • Smeeth L.
        • Guttmann A.
        • et al.
        The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.
        PLoS Med. 2015; 12: e1001885
        • Park J.H.
        • Jegal Y.
        • Shim T.S.
        • et al.
        Hypoxemia and arrhythmia during daily activities and six-minute walk test in fibrotic interstitial lung diseases.
        J Korean Med Sci. 2011; 26: 372-378
        • Jenkins S.
        • Cecins N.
        Six-minute walk test: observed adverse events and oxygen desaturation in a large cohort of patients with chronic lung disease.
        Intern Med J. 2011; 41: 416-422
        • Morris N.R.
        • Seale H.
        • Harris J.
        • Hall K.
        • Hopkins P.
        • Kermeen F.
        Serious adverse events during a 6-min walk test in patients with pulmonary hypertension.
        Eur Respir J. 2015; 45: 1179-1182
        • Galie N.
        • Humbert M.
        • Vachiery J.L.
        • et al.
        2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
        Eur Respir J. 2015; 46: 903-975
        • Egan T.M.
        • Murray S.
        • Bustami R.T.
        • et al.
        Development of the new lung allocation system in the United States.
        Am J Transplant. 2006; 6: 1212-1227